Hepatitis B
Are IL28B Gene Variations Associated with Outcomes in People with Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Friday, 12 November 2010 12:48
- Written by Liz Highleyman
IL28B gene patterns may influence response to interferon therapy for hepatitis B, but this is not as straightforward as it is for hepatitis C, according to a set of studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. Two analyses suggested that people with the protective rs12979860 C/C pattern were more likely to achieve sustained virological suppression with interferon, but less likely to experience HBeAg seroconversion. A third study, however, found no link between rs12979860 pattern and hepatitis B or HIV persistence or progression.
Add-on Adefovir Is More Effective and Durable Than Switch to Entecavir as Rescue Therapy
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 November 2010 12:48
- Written by Liz Highleyman
Adding adefovir (Hepsera) is more effective and durable than switching to entecavir (Baraclude) as rescue therapy for Epivir-resistant patients with chronic hepatitis B, according to a study presented in Boston last week at AASLD 2010. The mean reduction of serum HBV DNA levels was significantly less in the entecavir group than in the add-on adefovir group at weeks 24 and 48. In addition, the rate of undetectable HBV DNA was significantly lower in the entecavir group than in the add-on adefovir group.
FDA Approves Entecavir (Baraclude) for Chronic Hepatitis B Patients with Decompensated Liver Disease
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 19 October 2010 12:49
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration announced this week that it has approved the use of entecavir (Baraclude) to treat chronic hepatitis B virus (HBV) infection in people with decompensated liver disease, or liver failure. The expanded indication is supported by results from a Phase 3 trial showing that entecavir was more effective than adefovir (Hepsera) for this hard-to-treat patient population.
Telbivudine and Elective Cesarean Section Help Prevent Mother-to-child Hepatitis B Transmission
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 November 2010 12:48
- Written by Liz Highleyman
Treatment with the nucleoside analog telbivudine (Tyzeka) and birth by elective Cesarean section both reduced the likelihood of hepatitis B virus (HBV) transmission from mothers to infants during pregnancy and delivery, according to 2 separate studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. Emergency Cesarean delivery, however, was associated with a trend toward increased transmission risk.
Add-on adefovir (Hepsera) Is More Effective and Durable Than a Switch to entecavir (Baraclude) as Rescue Therapy for Epivir-resistant Patients with Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 19 October 2010 02:10
- Written by HIVandHepatitis.com
Adding Hepsera is more effective and durable than switching to Baraclude as rescue therapy for Epivir-resistant patients with chronic hepatitis B, according to a study presented in Boston last week at AASLD 2010. The mean reduction of serum HBV DNA levels was significantly less in the Entecavir group than in the add-on Hepsera group at weeks 24 and 48. In addition, the rate of undetectable HBV DNA was significantly lower in the Entecavir group than in the add-on Hepsera group.
Which Pegylated Interferon alfa-2b Regimen Works Best for Chronic Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Friday, 05 November 2010 12:48
- Written by Liz Highleyman
People with hepatitis B "e" antigen (HBeAg) positive chronic hepatitis B virus (HBV) infection respond best to a regimen of pegylated interferon alfa-2b (PegIntron) administered at 1.5 mcg/kg/week for 48 weeks, compared with a lower dose and/or shorter duration, according to a Chinese study presented last week at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston.
AASLD and Trust for America's Health Call for Action on Hepatitis B and C
- Details
- Category: HBV Policy & Advocacy
- Published on Tuesday, 05 October 2010 13:42
- Written by Trust for America's Health
Millions of Americans are living with chronic hepatitis B or C, but many do not know they are infected and are not receiving appropriate care, according to a new report issued by the American Association for the Study of Liver Diseases (AASLD) and the Trust for America's Health (TFAH). Over years or decades, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection can cause advanced liver disease -- including liver cirrhosis and hepatocellular carcinoma -- which is projected to be a growing public health concern in the coming years.
Tenofovir (Viread) Maintains HBV Suppression without Resistance for 4 Years
- Details
- Category: HBV Treatment
- Published on Monday, 01 November 2010 12:48
- Written by Press Release
The nucleotide analog tenofovir (Viread) continued to demonstrate potent activity against hepatitis B virus (HBV) through 4 years, researchers reported at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. In preliminary analyses from Study 102 (HBeAg negative patients) and Study 103 (HBeAg positive patients), HBV viral load remained suppressed, tenofovir was well-tolerated with only a few cases of elevated creatinine (a marker of impaired kidney function), and no drug-resistance mutations were detected. Subgroup analyses from the same studies showed that tenofovir worked well for Asian participants and people with high baseline HBV viral load.
FDA Approves New Roche Hepatitis B Viral Load Test
- Details
- Category: HBV Testing & Diagnosis
- Published on Friday, 01 October 2010 12:49
- Written by Roche
Roche Molecular Diagnostics last week received approval from the U.S. Food and Drug Administration (FDA) for a next-generation hepatitis B virus (HBV) DNA test. The automated blood test can be used to determine HBV viral load in people considering or receiving antiviral treatment.
More Articles...
- Lymphoma Chemotherapy Can Cause Severe Hepatitis B Reactivation
- Nearly 20% of New Hepatitis B Infections May Occur in Healthcare Settings
- Androgen Receptor May Explain Why More Men with Hepatitis B Develop Liver Cancer
- Pegylated Interferon Has Low Sustained Response Rate in HBeAg Negative Chronic Hepatitis B Patients
- Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients
Web Design and Development by